Serina Therapeutics (SER) Net Income (2018 - 2026)
Serina Therapeutics (SER) posted Net Income of -$6.4 million for Q4 2025, up 0.58% sequentially from -$6.4 million in Q3 2025, and down 7.95% YoY from -$6.9 million in Q4 2024.
Serina Therapeutics (SER) Net Income (2018 - 2026) Analysis & Trends
Serina Therapeutics has reported Net Income for 8 years, with the latest figure at -$6.4 million in Q4 2025.
- Quarterly Net Income fell 7.95% year-over-year to -$6.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$25.0 million (down 33.03% YoY) and the FY2025 annual result came in at -$19.2 million, down 71.46% from the prior year.
- Net Income grew to -$6.4 million in Q4 2025 per SER's latest filing, from -$6.4 million in the prior quarter.
- Over five years, Net Income peaked at $435000.0 in Q4 2023 and troughed at -$6.4 million in Q3 2025.
- A 5-year average of -$3.0 million and a median of -$2.6 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2023: Net Income plunged 37500.0% in 2022, then soared 124.41% in 2023.
- Over 5 years, Net Income stood at -$7000.0 in 2021, then slumped by 25357.14% to -$1.8 million in 2022, then surged by 124.41% to $435000.0 in 2023, then plunged by 1458.39% to -$5.9 million in 2024, then fell by 7.95% to -$6.4 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$6.4 million, -$6.4 million, and -$6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 81.49 Mn |
| 10 | Serina Therapeutics | 43.42 Mn | 20.40 Mn | - | -6.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.73 Mn |
| Dec 31, 2025 | -6.38 Mn |
| Sep 30, 2025 | -6.42 Mn |
| Jun 30, 2025 | -5.96 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | -5.91 Mn |
| Sep 30, 2024 | -5.43 Mn |
| Jun 30, 2024 | -4.48 Mn |
| Mar 31, 2024 | -3.00 Mn |
| Dec 31, 2023 | 435,000.00 |
| Sep 30, 2023 | -1.56 Mn |
| Jun 30, 2023 | -1.05 Mn |
| Mar 31, 2023 | -1.05 Mn |
| Dec 31, 2022 | -1.78 Mn |
| Sep 30, 2022 | -2.44 Mn |
| Jun 30, 2022 | -2.62 Mn |
| Mar 31, 2022 | -2.71 Mn |
| Sep 30, 2021 | -7,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Mar 31, 2021 | -103,000.00 |